NCT06607276View on ClinicalTrials.gov

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

PHASE2RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

September 20, 2026

Study Completion Date

September 20, 2027

Conditions
Cholangiocarcinoma CancerAdebrelimab (SHR-1316)
Interventions
DRUG

Adebrelimab and capecitabine

Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles

DRUG

capecitabine

capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles

Trial Locations (4)

210000

NOT_YET_RECRUITING

Jinling Hospital, Nanjing

210002

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

240000

NOT_YET_RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

280000

NOT_YET_RECRUITING

Yancheng NO.1 People's Hospital, Yancheng

All Listed Sponsors
collaborator

Jinling Hospital, China

OTHER

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER